DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/07/22
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial ResultsBusiness Wire • 05/04/22
DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022Business Wire • 04/28/22
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/15/22
DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial ResultsBusiness Wire • 03/14/22
DiaMedica Therapeutics to Report Fourth Quarter 2021 Financial Results and Provide a Business Update March 15, 2022Business Wire • 03/08/22
DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial OfficerBusiness Wire • 02/02/22
DiaMedica Therapeutics to Present Research at International Stroke ConferenceBusiness Wire • 01/25/22
DiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access EventBusiness Wire • 12/13/21
DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare ConferenceBusiness Wire • 11/17/21
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/11/21
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial ResultsBusiness Wire • 11/10/21
DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021Business Wire • 11/09/21
DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS TrialBusiness Wire • 11/08/21
DiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021Business Wire • 11/04/21
DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021Business Wire • 10/18/21
DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic StrokeBusiness Wire • 09/30/21
DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic StrokeBusiness Wire • 09/13/21